CoChat

Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

Open access
Zhang, Wei, Liu, Bo, Wu, Wenhui, Li, Likun, Broom, Bradley M., Basourakos, Spyridon P., Korentzelos, Dimitrios, Luan, Yang, Wang, Jianxiang, Yang, Guang, Park, Sanghee, Azad, Abul Kalam, Cao, Xuhong, Kim, Jeri, Corn, Paul G., Logothetis, Christopher J., Aparicio, Ana M., Chinnaiyan, Arul M., Navone, Nora, Troncoso, Patricia, Thompson, Timothy C. · 2018 · Clinical Cancer Research
Cited by 99

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Purpose: We investigated MYCN-regulated molecular pathways in castration-resistant prostate cancer (CRPC) classified by morphologic criteria as adenocarcinoma or neuroendocrine to extend the molecular phenotype, establish driver pathways, and identify novel approaches to combination therapy for neuroendocrine prostate cancer (NEPC). Experimental Design and Results: Using comparative bioinformatics analyses of CRPC-Adeno and CRPC-Neuro RNA sequence data from public data sets and a panel of 28 PDX models, we identified a MYCN–PARP–DNA damage response (DDR) pathway that is enriched in CRPC with neuroendocrine differentiation (NED) and CRPC-Neuro. ChIP-PCR assay revealed that N-MYC transcriptionally activates PARP1, PARP2, BRCA1, RMI2, and TOPBP1 through binding to the promoters of these genes. MYCN or PARP1 gene knockdown significantly reduced the expression of MYCN–PARP–DDR pathway genes and NED markers, and inhibition with MYCNsi and/or PARPsi, BRCA1si, or RMI2si significantly suppressed malignant activities, including cell viability, colony formation, and cell migration, in C4-2b4 and NCI-H660 cells. Targeting this pathway with AURKA inhibitor PHA739358 and PARP inhibitor olaparib generated therapeutic effects similar to those of gene knockdown in vitro and significantly suppressed tumor growth in both C4-2b4 and MDACC PDX144-13C subcutaneous models in vivo. Conclusions: Our results identify a novel MYCN–PARP–DDR pathway that is driven by N-MYC in a subset of CRPC-Adeno and in NEPC. Targeting this pathway using in vitro and in vivo CRPC-Adeno and CRPC-Neuro models demonstrated a novel therapeutic strategy for NEPC. Further investigation of N-MYC–regulated DDR gene targets and the biological and clinical significance of MYCN–PARP–DDR signaling will more fully elucidate the importance of the MYCN–PARP–DDR signaling pathway in the development and maintenance of NEPC. Clin Cancer Res; 24(3); 696–707. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1872

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 99

Metadata

Authors
Zhang, W., Liu, B., Wu, W., Li, L., Broom, B. M., Basourakos, S. P., Korentzelos, D., Luan, Y., Wang, J., Yang, G., Park, S., Azad, A. K., Cao, X., Kim, J., Corn, P. G., Logothetis, C. J., Aparicio, A. M., Chinnaiyan, A. M., Navone, N., Troncoso, P., & Thompson, T. C.
Venue
Clinical Cancer Research
Published
2018-01-31
Volume
24
Issue
3
Pages
696-707
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2769445989
Cited by
99
References
3
FWCI
6.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1872
The paper
Zhang, W., Liu, B., Wu, W., Li, L., Broom, B. M., Basourakos, S. P., Korentzelos, D., Luan, Y., Wang, J., Yang, G., Park, S., Azad, A. K., Cao, X., Kim, J., Corn, P. G., Logothetis, C. J., Aparicio, A. M., Chinnaiyan, A. M., Navone, N., . . . Thompson, T. C. (2018). Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1872

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.